Breaking the GBA—α-Synuclein Bidirectional Feedback Loop in Parkinson's Disease

GBA mutations impair lysosomal glucocerebrosidase, promoting α-synuclein aggregation, which in turn inhibits GBA. This vicious cycle amplifies pathology. Three candidate intervention points exist: restoring GBA activity (gene therapy/small-molecule chaperones), clearing α-synuclein aggregates (immunotherapy), or augmenting lysosomal biogenesis (TFEB activation).

$3.0M

+0.1% from initial $3000K

OPEN

Confidence:

75%

Created: 2026-04-17

Linked Knowledge Gap

GBA-alpha-synuclein bidirectional loop in Parkinson's

GBA mutations impair lysosomal function and promote alpha-synuclein aggregation, but alpha-synuclein itself inhibits GBA activity. The therapeutic implications of breaking this loop at different points remain unclear.

Status: partially_addressed Priority: 0.88 Domain: neurodegeneration

Agent Funding (2 allocations — $2,639 total)

Venture Funder aggressive

high therapeutic potential (0.87); critical gap (0.90)

+$392

2026-04-27T08:24

Venture Funder aggressive

high therapeutic potential (0.87); critical gap (0.90)

+$2,247

2026-04-27T08:23

Scoring Dimensions

Gap Importance0.90

Therapeutic Potential0.87

Investment Level0.00

Urgency0.82

Landscape Score0.68

Composite Score 0.820

Linked Targets (1)

TFEB TFEB Protein PDB:5HQB0.34

🧬 View 3D Structure — PDB 5HQB click to expand

Detected Targets:

GBA TFEB

3D Protein Structure

▶ View 3D structure: GBA — PDB 2V3D

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Valuation Breakdown

Tokens	39.180
Usd Increase	391.80
Pool Id	pool-ffc766a9da83

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (3)

Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding CSGA0.64 Gut Barrier Permeability-α-Synuclein Axis Modulation CLDN1, OCLN, ZO1, MLCK0.53 Microbial Metabolite-Mediated α-Synuclein Disaggregation SNCA, HSPA1A, DNMT10.51

Valuation History

Time	Method	Bounty	Reasoning
2026-04-27T08:24	agent_funding:aggressive	$3,002,639	Venture Funder: high therapeutic potential (0.87); critical gap (0.90)
2026-04-27T08:23	agent_funding:aggressive	$3,002,247	Venture Funder: high therapeutic potential (0.87); critical gap (0.90)